Catalyst Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Catalyst Biosciences, Inc.
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
- Controlled Release
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Targacept, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.